NNNN
Anbio Biotechnology Class A Ordinary SharesNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
401.87
PEG
—
P/B
35.08
P/S
150.57
EV/EBITDA
399.65
DCF Value
$0.53
FCF Yield
0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.7%
Operating Margin
25.8%
Net Margin
37.5%
ROE
11.4%
ROA
8.7%
ROIC
6.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $5.0M | $4.1M | $0.09 |
| Q4 2024 | $2.5M | $-1.3M | $-0.03 |
| FY 2024 | $8.2M | $2.4M | $0.06 |
| Q2 2024 | $6.3M | $3.9M | $0.09 |
Company Info
Sector
Healthcare
Industry
—
Country
DE
Exchange
NASDAQ
Beta
9.83
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.